Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | The role of NK cells in preventing relapse in leukemia

Monika Holubová • 21 Mar 2022
EBMT 2022
Leukemia

Monika Holubová, PhD, Charles University Faculty of Medicine, Pilsen, Czech Republic, talks on the potential role of natural killer (NK) cells in relapse control after haploidentical stem cell transplantation (SCT) in leukemia. Following treatment, tumor cells are damaged and express stress-associated molecules which allow them to be recognized and killed by NK cells. The success of this mechanism is variable. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Monika Holubová

Perspectives on allogeneic NK cell-based immunotherapy
1:57
Perspectives on allogeneic NK cell-based immunotherapy
Monika Holubová • 21 Mar 2022

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals